Giraudet Anne-Laure, Kryza David, Hofman Michael, Moreau Aurélie, Fizazi Karim, Flechon Aude, Hicks Rodney J, Tran Ben
Nuclear Medicine Department LUMEN, Regional Cancer Research Centre Leon Berard, 15 rue Gabriel Sarrazin, 69373 Lyon, France.
Nuclear Medicine Department LUMEN, Regional Cancer Research Centre Leon Berard, Lyon, France.
Ther Adv Med Oncol. 2021 Oct 26;13:17588359211053898. doi: 10.1177/17588359211053898. eCollection 2021.
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this protein have been created over the past decade and numerous clinical studies have positively demonstrated the tolerance and efficacy of radiolabeled prostate-specific membrane antigen ligands for PSMA radioligand therapy (PRLT). Preliminary results are encouraging that PRLT will become an important addition to the current therapeutic options in a number of settings. Improvement in radiopharmaceutical targeting and combination with other oncological agents are under investigation to further improve its therapeutic efficacy. These encouraging results have led to the development of other therapies using PSMA as a target, such as PSMA-targeted chimeric antigen receptor T-cells, PSMA-targeted antibody drug conjugates, and PSMA-targeted bi-specific T-cell-directed therapy. This narrative review details the current state and advancements in prostate-specific membrane antigen targeting in prostate cancer treatment.
前列腺特异性膜抗原（PSMA）在大多数前列腺癌细胞膜上高度表达，在正常组织中表达程度较低。在过去十年中，已经构建了许多靶向该蛋白的载体，并且大量临床研究已肯定地证明了放射性标记的前列腺特异性膜抗原配体用于PSMA放射性配体疗法（PRLT）的耐受性和有效性。初步结果令人鼓舞，表明PRLT将在许多情况下成为当前治疗选择的重要补充。目前正在研究改进放射性药物靶向以及与其他肿瘤药物联合使用，以进一步提高其治疗效果。这些令人鼓舞的结果促使了以PSMA为靶点的其他疗法的发展，如PSMA靶向嵌合抗原受体T细胞、PSMA靶向抗体药物偶联物和PSMA靶向双特异性T细胞导向疗法。这篇叙述性综述详细介绍了前列腺癌治疗中前列腺特异性膜抗原靶向的现状和进展。
